Finance

Lists
BMYB34:BVMF
Bristol-Myers Squibb Company BDR
၃၃၁.၉၀ R$
+၀.၆၅%
(+၂.၁၅) 1D
စက် ၃၀, GMT-၃ ၁၁:၃၁:၂၅  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for BMYB34...
Mkt. cap
ဋေ ၁.၂၁ သ
Avg. vol.
၃.၀၀
Volume
၀.၀၀
52-wk high
၃၄၇.၁၅ R$
52-wk low
၂၂၁.၇၂ R$
Shares outstanding
၂၀၄.၂၇ ဋေ
No. of employees
၃ သောင်း
Mkt. cap
ဋေ ၁.၂၁ သ
Avg. vol.
၃.၀၀
Volume
၀.၀၀
52-wk high
၃၄၇.၁၅ R$
52-wk low
၂၂၁.၇၂ R$
Shares outstanding
၂၀၄.၂၇ ဋေ
No. of employees
၃ သောင်း
News stories
From web sources and news partners
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Company BDR
CEOChris Boerner
Employees၃.၂၅ သောင်း
Founded၁၈၈၇
Headquartersနယူးယောက်မြို့, နယူးယောက်ပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitebms.com
Last report
၂၀၂၆ ဇူ ၃၀
Fiscal period
Q2 2026
၂.၀၄ US$ / ၁.၆၀ US$
+၂၇.၇၄%beat
Revenue / Est. (USD)
ဋေ ၁.၃၀ ထ / ဋေ ၁.၁၇ ထ
+၁၀.၅၃%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
ဋေ ၁.၂၂ ထ
ဋေ ၁.၂၅ ထ
ဋေ ၁.၁၅ ထ
ဋေ ၁.၃၀ ထ
Cost of goods sold
၃၃၁.၂၀ ဋေ
၃၅၀.၇၀ ဋေ
၃၄၀.၈၀ ဋေ
၃၇၁.၁၀ ဋေ
Cost of revenue
၃၃၁.၂၀ ဋေ
၃၅၀.၇၀ ဋေ
၃၄၀.၈၀ ဋေ
၃၇၁.၁၀ ဋေ
Research and development expenses
၂၄၃.၃၀ ဋေ
၂၅၆.၁၀ ဋေ
၂၂၃.၈၀ ဋေ
၂၅၃.၆၀ ဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၁၇၈.၈၀ ဋေ
၂၀၈.၇၀ ဋေ
၁၆၁.၀၀ ဋေ
၁၈၂.၄၀ ဋေ
Operating expense
၅၀၅.၂၀ ဋေ
၅၄၇.၄၀ ဋေ
၄၂၈.၅၀ ဋေ
၄၇၉.၇၀ ဋေ
Total operating expenses
၈၃၆.၄၀ ဋေ
၈၉၈.၁၀ ဋေ
၇၆၉.၃၀ ဋေ
၈၅၀.၈၀ ဋေ
Operating income
၃၈၅.၈၀ ဋေ
၃၅၂.၁၀ ဋေ
၃၇၉.၆၀ ဋေ
၄၄၆.၅၀ ဋေ
Other non operating income
၅၂.၉၀ ကုဋေ
၅၄.၄၀ ကုဋေ
၁၂.၅၀ ကုဋေ
၁၀.၆၀ ကုဋေ
EBT including unusual items
၃၁၁.၄၀ ဋေ
၁၄၇.၀၀ ဋေ
၃၂၃.၉၀ ဋေ
၄၀၈.၆၀ ဋေ
EBT excluding unusual items
၄၀၆.၇၀ ဋေ
၃၈၆.၄၀ ဋေ
၃၆၅.၄၀ ဋေ
၄၃၄.၆၀ ဋေ
Income tax expense
၉၁.၉၀ ကုဋေ
၃၈.၄၀ ကုဋေ
၅၆.၁၀ ကုဋေ
၇၇.၀၀ ကုဋေ
Effective tax rate
၂၉.၅၁%
၂၆.၁၂%
၁၇.၃၂%
၁၈.၈၄%
Other operating expenses
-
-
-
-
Net income
၂၂၀.၁၀ ဋေ
၁၀၈.၇၀ ဋေ
၂၆၇.၇၀ ဋေ
၃၃၁.၇၀ ဋေ
Net profit margin
၁၈.၀၁%
၈.၆၉%
၂၃.၃၀%
၂၅.၅၇%
Earnings per share
၁.၆၃
၁.၂၆
၁.၅၈
၂.၀၄
Interest and investment income
၁၆.၁၀ ကုဋေ
၁၄.၈၀ ကုဋေ
၁၀.၄၀ ကုဋေ
၁၀.၁၀ ကုဋေ
Interest expense
-၄၈.၂၀ ကုဋေ
-၄၃.၂၀ ကုဋေ
-၄၀.၆၀ ကုဋေ
-၄၀.၃၀ ကုဋေ
Net interest expenses
-၃၂.၁၀ ကုဋေ
-၂၈.၄၀ ကုဋေ
-၃၀.၂၀ ကုဋေ
-၃၀.၂၀ ကုဋေ
Depreciation and amortization charges
-
-
-
-
EBITDA
၄၉၀.၈၀ ဋေ
၄၅၄.၅၀ ဋေ
၄၄၀.၇၀ ဋေ
၅၀၇.၆၀ ဋေ
Gain or loss from assets sale
-၉.၀၀ သန်း
-
-၃.၄၀ ကုဋေ
-၁၄.၂၀ ကုဋေ
AI content may include mistakes. Learn more
Google အက်ပ်များ